TOPCHOICE MEDICAL CO., INC. Financials Topchoice Medical Co., Inc.
Equities
600763
CNE000000MZ8
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.44 CNY | +7.87% |
|
+13.82% | -20.94% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 32,875 | 88,663 | 63,807 | 49,055 | 24,513 | 19,379 | - | - |
| Enterprise Value (EV) 1 | 32,773 | 88,275 | 63,240 | 48,594 | 24,327 | 17,891 | 17,173 | 19,379 |
| P/E ratio | 71.2 x | 180 x | 90.9 x | 89.5 x | 49 x | 34.3 x | 22.5 x | - |
| Yield | - | - | - | - | 0.57% | 0.06% | - | - |
| Capitalization / Revenue | 17.4 x | 42.5 x | 22.9 x | 18 x | 8.61 x | 6.24 x | 4.84 x | 4.83 x |
| EV / Revenue | 17.3 x | 42.3 x | 22.7 x | 17.9 x | 8.55 x | 5.76 x | 4.29 x | 4.83 x |
| EV / EBITDA | 45.5 x | 114 x | 58.5 x | 56.4 x | 28.5 x | 18.2 x | 13.5 x | - |
| EV / FCF | - | - | 111 x | 195 x | 72.7 x | 32 x | 26 x | 20.9 x |
| FCF Yield | - | - | 0.9% | 0.51% | 1.38% | 3.12% | 3.84% | 4.79% |
| Price to Book | 18.4 x | 41.2 x | 22.2 x | 14.8 x | 6.44 x | 4.15 x | 3.47 x | - |
| Nbr of stocks (in thousands) | 320,640 | 320,640 | 320,640 | 320,640 | 320,640 | 320,640 | - | - |
| Reference price 2 | 102.5 | 276.5 | 199.0 | 153.0 | 76.45 | 60.44 | 60.44 | 60.44 |
| Announcement Date | 4/23/20 | 4/9/21 | 4/27/22 | 4/27/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,894 | 2,088 | 2,781 | 2,719 | 2,847 | 3,107 | 4,005 | 4,013 |
| EBITDA 1 | 720.2 | 771.5 | 1,081 | 861.6 | 852.4 | 984.3 | 1,274 | - |
| EBIT 1 | 633.8 | 678.6 | 974.9 | 733.9 | 711.9 | 767.7 | 1,164 | - |
| Operating Margin | 33.46% | 32.5% | 35.06% | 27% | 25.01% | 24.71% | 29.07% | - |
| Earnings before Tax (EBT) 1 | 633.4 | 680.1 | 974.6 | 738 | 708.9 | 788.8 | 1,171 | - |
| Net income 1 | 463.1 | 492.6 | 702.8 | 548.3 | 500.5 | 555.6 | 880.7 | - |
| Net margin | 24.45% | 23.59% | 25.27% | 20.17% | 17.58% | 17.88% | 21.99% | - |
| EPS 2 | 1.440 | 1.540 | 2.190 | 1.710 | 1.560 | 1.764 | 2.681 | - |
| Free Cash Flow 1 | - | - | 572.1 | 249.1 | 334.5 | 559 | 660 | 929 |
| FCF margin | - | - | 20.57% | 9.16% | 11.75% | 17.99% | 16.48% | 23.15% |
| FCF Conversion (EBITDA) | - | - | 52.91% | 28.92% | 39.24% | 56.79% | 51.8% | - |
| FCF Conversion (Net income) | - | - | 81.4% | 45.44% | 66.84% | 100.62% | 74.94% | - |
| Dividend per Share 2 | - | - | - | - | 0.4350 | 0.0370 | - | - |
| Announcement Date | 4/23/20 | 4/9/21 | 4/27/22 | 4/27/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 663.5 | 821.2 | 579.2 | 674.5 | 688.1 | 822.2 | 661.7 | 708.4 | 752 | 930 | 656 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | 175.1 | 282 | 51.96 | 225 | 176.8 | 282.4 | 27.71 | - | - | - | - |
| Operating Margin | - | 26.38% | 34.34% | 8.97% | 33.36% | 25.69% | 34.35% | 4.19% | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | 51.38 | 224.7 | 176.2 | 282.1 | - | - | - | - | - |
| Net income | 166.5 | - | - | 33.1 | 169 | 135.4 | 207.3 | - | - | - | - | - |
| Net margin | - | - | - | 5.71% | 25.05% | 19.68% | 25.22% | - | - | - | - | - |
| EPS 2 | 0.5200 | 0.4000 | 0.6900 | 0.1000 | 0.5300 | 0.4200 | 0.6500 | -0.0400 | 0.5400 | 0.4400 | 0.7000 | 0.1900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/27/22 | 8/22/22 | 10/24/22 | 4/27/23 | 4/27/23 | 8/24/23 | 10/24/23 | 4/25/24 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 103 | 389 | 568 | 461 | 186 | 1,488 | 2,206 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 572 | 249 | 335 | 559 | 660 | 929 |
| ROE (net income / shareholders' equity) | 29.9% | 24.4% | 27.9% | 17.6% | 14.1% | 13.8% | 16.2% | - |
| ROA (Net income/ Total Assets) | 19.3% | 17.1% | 17.5% | 10.8% | - | 8.9% | 9.87% | - |
| Assets 1 | 2,396 | 2,877 | 4,010 | 5,055 | - | 6,242 | 8,926 | - |
| Book Value Per Share 2 | 5.570 | 6.710 | 8.980 | 10.30 | 11.90 | 14.60 | 17.40 | - |
| Cash Flow per Share 2 | 2.020 | 2.210 | 2.930 | 2.090 | 2.620 | 2.870 | 3.250 | - |
| Capex 1 | 126 | 166 | 367 | 421 | 505 | 381 | 248 | 380 |
| Capex / Sales | 6.64% | 7.94% | 13.21% | 15.48% | 17.76% | 12.26% | 6.19% | 9.47% |
| Announcement Date | 4/23/20 | 4/9/21 | 4/27/22 | 4/27/23 | 4/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
60.44
CNY
Average target price
86.58
CNY
Spread / Average Target
+43.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.94% | 2.67B | |
| -21.25% | 2.91B | |
| -60.16% | 2.06B | |
| -25.10% | 323M | |
| -47.38% | 172M | |
| -27.37% | 123M |
- Stock Market
- Equities
- 600763 Stock
- Financials Topchoice Medical Co., Inc.
